Literature DB >> 10488810

Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment.

A Chamorro1, N Vila, C Ascaso, R Blanc.   

Abstract

BACKGROUND: The risk-benefit ratio of early vs late heparinization for acute stroke with nonvalvular atrial fibrillation remains unsettled.
OBJECTIVE: To clarify the relationship between timing to heparinization and functional outcome in acute cardioembolic stroke.
DESIGN: Consecutive case series.
SETTING: Referral center. PATIENTS: In 231 patients with stroke and nonvalvular atrial fibrillation, intravenous or subcutaneous heparin administered with the goal of achieving an activated partial thromboplastin time (APTT) 1.5 to 2.0 times control values. Delay to the initiation of heparin therapy was less than 6 hours from the onset of symptoms in 74 patients and between 6 and 48 hours in 157 patients. Functional outcome (Rankin scale) was assessed 9 +/- 3 (mean +/- SD) days from stroke onset using multivariate analysis and including in the model treatment delay, risk factors (eg, age, hypertension, diabetes, hypercholesterolemia, previous stroke, and heart disease), initial neurological severity, and baseline computed tomographic findings (eg, early signs of infarction and white matter abnormalities). Clinical symptoms on admission (Mathew score) and baseline radiological findings were evaluated in all subjects. The bleeding rate was assessed on subsequent computed tomographic (CT) scans (obtained 7 +/- 2 days after stroke). The relationship between APTT ratios and stroke recurrence or hemorrhagic worsening was also tested. MAIN OUTCOME MEASURES: Functional outcome at hospital discharge and incidence of early recurrent strokes and bleeding complications.
RESULTS: Mortality (9%), hemorrhagic worsening (3.4%), and early stroke recurrence (2.1%) occurred in the hospital. Complete recovery was associated with age younger than 70 years (odds ratio [OR], 0.21; 95% confidence interval [CI], 0.05-0.70), a baseline Mathew score higher than 74 (OR, 11.5; 95% CI, 4.95-26.70), normal baseline CT findings (OR, 8.86; CI, 3.99-19.60), and early heparinization (OR, 1.7; 95% CI, 1.10-2.50). Targeted APTT ratios were achieved at 24 hours in fewer than 50% of patients. Whereas stroke recurrence was associated with lower mean APTT ratios, higher mean APTT ratios were observed in patients with symptomatic bleeding, especially on the day of bleeding. Age, admission stroke severity, blood pressure, and baseline CT findings did not predict hemorrhagic worsening.
CONCLUSIONS: Delaying anticoagulation in alert patients with stroke and nonvalvular atrial fibrillation is not endorsed by the initial severity of symptoms or the early signs of infarction on CT scan. Functional recovery is improved the sooner heparin is administered. These findings suggest that heparin also has therapeutic properties. However, close APTT monitoring is warranted to lessen the incidence of untoward complications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488810     DOI: 10.1001/archneur.56.9.1098

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  10 in total

1.  Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke.

Authors:  Eva A Rocha; Ruijun Ji; Hakan Ay; Zixiao Li; Ethem Murat Arsava; Gisele S Silva; Alma Gregory Sorensen; Ona Wu; Aneesh B Singhal
Journal:  J Stroke Cerebrovasc Dis       Date:  2019-03-29       Impact factor: 2.136

Review 2.  Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.

Authors:  D J H McCabe; R D Rakhit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

3.  Symptomatic intracerebral hematomas in posterior circulation stroke patients anticoagulated with heparin.

Authors:  Kyusik Kang; Byung-Woo Yoon
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 4.  Evaluation and management of acute ischemic stroke.

Authors:  Birgitte H Bendixen; Lenore Ocava
Journal:  Curr Cardiol Rep       Date:  2002-03       Impact factor: 2.931

Review 5.  Selection of anticoagulants or antiplatelet-aggregating agents for prevention of stroke.

Authors:  Eugene D Kaplan; Ralph L Sacco
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

Review 6.  Cardioembolic stroke: An update on etiology, diagnosis and management.

Authors:  Megan C Leary; Louis R Caplan
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.714

7.  Antithrombotic therapy in cardiac embolism.

Authors:  Alvaro Cervera; Angel Chamorro
Journal:  Curr Cardiol Rev       Date:  2010-08

8.  Anticoagulation after cardioembolic stroke: to bridge or not to bridge?

Authors:  Hen Hallevi; Karen C Albright; Sheryl Martin-Schild; Andrew D Barreto; Sean I Savitz; Miguel A Escobar; Nicole R Gonzales; Elizabeth A Noser; Kachi Illoh; James C Grotta
Journal:  Arch Neurol       Date:  2008-07-14

9.  Anticoagulant therapy with a selective thrombin inhibitor for acute cerebral infarction: usefulness of coagulation markers for evaluation of efficacy.

Authors:  Takao Urabe; Ryota Tanaka; Kazuyuki Noda; Yoshikuni Mizuno
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

10.  Risks and benefits of early antithrombotic therapy after thrombolytic treatment in patients with acute stroke.

Authors:  Sergio Amaro; Laura Llull; Xabier Urra; Víctor Obach; Álvaro Cervera; Ángel Chamorro
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.